Chronic administration of dimebon does not ameliorate amyloid-β pathology in 5xFAD transgenic mice

Journal of Alzheimer's Disease

Volumn 36, Issue 3, 2013, Pages 589-596

  Peters, Owen M ^a,g   Shelkovnikova, Tatyana ^a,b   Tarasova, Tatiana ^b,e   Springe, Signe ^a   Kukharsky, Michail S ^b   Smith, Gaynor A ^c   Brooks, Simon ^a   Kozin, Sergey A ^d   Kotelevtsev, Yury ^e,f   Bachurin, Sergey O ^b   Ninkina, Natalia ^a,b,d   Buchmana, Vladimir L ^a,b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b INSTITUTE OF PHYSIOLOGICALLY ACTIVE COMPOUNDS   (Russian Federation)

^c MCLEAN HOSPITAL   (United States)

^d ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^e PUSHCHINO STATE UNIVERSITY   (Russian Federation)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer's disease; dimebolin; latrepirdine; tauopathy; therapeutics; transgenic mice

Indexed keywords

AMYLOID BETA PROTEIN; DIMEBON;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; BEHAVIOR CHANGE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; GENETIC ASSOCIATION; HIPPOCAMPUS; LEARNING; LOCOMOTION; MALE; MAZE TEST; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SENSORIMOTOR FUNCTION; SOMATOSENSORY CORTEX;

EID: 84881430418     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130071     Document Type: Article

References (27)

1. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D (2008) Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: A randomised, double-blind, placebo-controlled study. Lancet 372, 207-215
2. Jones RW (2010) Dimebon disappointment. Alzheimers Res Ther 2, 25
3. Bachurin S, Bukatina E, Lermontova N, Tkachenko S, Afanasiev A, Grigoriev V, Grigorieva I, Ivanov Y, Sablin S, Zefirov N (2001) Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci 939, 425-435
4. Grigorev VV, Dranyi OA, Bachurin SO (2003) Comparative study of action mechanisms of dimebon and memantine on AMPA-And NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull Exp Biol Med 136, 474-477
5. Schaffhauser H, Mathiasen JR, Dicamillo A, Huffman MJ, Lu LD, McKenna BA, Qian J, Marino MJ (2009) Dimebolin is a 5-HT6 antagonist with acute cognition enhancing activities. Biochem Pharmacol 78, 1035-1042
6. Giorgetti M, Gibbons JA, Bernales S, Alfaro IE, Drieu La Rochelle C, Cremers T, Altar CA, Wronski R, Hutter-Paier B, Protter AA (2010) Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-Aspartate receptor antagonism. J Pharmacol Exp Ther 333, 748-757
7. Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO (2003) Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci 993, 334-339
8. Naga KK, Geddes JW (2011) Dimebon inhibits calciuminduced swelling of rat brain mitochondria but does not alter calcium retention or cytochrome C release. Neuromolecular Med 13, 31-36
9. Zhang S, Hedskog L, Petersen CA,Winblad B, AnkarcronaM (2010) Dimebon (latrepirdine) enhances mitochondrial function and protects neuronal cells from death. J Alzheimers Dis 21, 389-402
10. Bachurin SO, Shelkovnikova TA, Ustyugov AA, Peters O, Khritankova I, Afanasieva MA, Tarasova TV, Alentov II, Buchman VL, Ninkina NN (2011) Dimebon slows progression of proteinopathy in gamma-synuclein transgenic mice. Neurotox Res 22, 33-42
11. Shelkovnikova TA, Ustyugov AA, Millership S, Peters O, Anichtchik O, Spillantini MG, Buchman VL, Bachurin SO, Ninkina NN (2011) Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alpha-synuclein in dopaminergic neurons of transgenic mice. Neurodegener Dis 8, 430-437
12. Wang J, Ferruzzi MG, Varghese M, Qian X, Cheng A, Xie M, Zhao W, Ho L, Pasinetti GM (2011) Preclinical study of dimebon on beta-Amyloid-mediated neuropathology in Alzheimer's disease. Mol Neurodegener 6, 7
13. Steele JW, Kim SH, Cirrito JR, Verges DK, Restivo JL,Westaway D, Fraser P, Hyslop PS, Sano M, Bezprozvanny I, Ehrlich ME, Holtzman DM, Gandy S (2009) Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo. Mol Neurodegener 4, 51
14. Yamashita M, Nonaka T, Arai T, Kametani F, Buchman VL, Ninkina N, Bachurin SO, Akiyama H, Goedert M, Hasegawa M (2009) Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett 583, 2419-2424
15. Steele JW, Lachenmayer ML, Ju S, Stock A, Liken J, Kim SH, Delgado LM, Alfaro IE, Bernales S, Verdile G, Bharadwaj P, Gupta V, Barr R, Friss A, Dolios G, Wang R, Ringe D, Fraser P, Westaway D, St George-Hyslop PH, Szabo P, Relkin NR, Buxbaum JD, Glabe CG, Protter AA,Martins RN, Ehrlich ME, Petsko GA, Yue Z, Gandy S (2012) Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model. Mol Psychiatry, doi: 10.1038/mp.2012.106
16. Steele JW, Ju S, Lachenmayer ML, Liken J, Stock A, Kim SH, Delgado LM, Alfaro IE, Bernales S, Verdile G, Bharadwaj P, Gupta V, Barr R, Friss A, Dolios G,Wang R, Ringe D, Protter AA, Martins RN, Ehrlich ME, Yue Z, Petsko GA, Gandy S (2012) Latrepirdine stimulates autophagy and reduces accumulation of alpha-synuclein in cells and in mouse brain. Mol Psychiatry, doi: 10.1038/mp.2012.115
17. Bharadwaj PR, Verdile G, Barr RK, Gupta V, Steele JW, Lachenmayer ML, Yue Z, Ehrlich ME, Petsko G, Ju S, Ringe D, Sankovich SE, Caine JM, Macreadie IG, Gandy S, Martins RN (2012) Latrepirdine (Dimebon) enhances autophagy and reduces intracellular GFP-Abeta42 levels in yeast. J Alzheimers Dis 32, 949-967
18. Peters OM, Connor-Robson N, Sokolov VB, Aksinenko AY, Kukharsky MS, Bachurin SO, Ninkina N, Buchman VL (2013) Chronic administration of dimebon ameliorates pathology in TauP301S transgenic mice. J Alzheimers Dis 33, 1041-1049
19. Perez SE, Nadeem M, Sadleir KR, Matras J, Kelley CM, Counts SE, Vassar R, Mufson EJ (2012) Dimebon alters hippocampal amyloid pathology in 3xTg-AD mice. Int J Physiol Pathophysiol Pharmacol 4, 115-127
20. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R (2006) Intraneuronal beta-Amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. J Neurosci 26, 10129-10140
21. Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O (2012) Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Abeta aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol Aging 33, 196.e129-140
22. Nirogi R, Kandikere V, Mudigonda K, Komarneni P, Boggavarapu R (2009) Liquid chromatography-tandem mass spectrometry method for the quantification of dimebon in rat plasma and brain tissue. J Chromatogr B Analyt Technol Biomed Life Sci 877, 3563-3571
23. Ewers M, Morgan DG, GordonMN,Woodruff-PakDS(2006) Associative and motor learning in 12-month-old transgenic APP+PS1 mice. Neurobiol Aging 27, 1118-1128
24. Ninkina N, Peters O, Millership S, Salem H, van der Putten H, Buchman VL (2009) Gamma-synucleinopathy: Neurodegeneration associated with overexpression of the mouse protein. Hum Mol Genet 18, 1779-1794
25. Vignisse J, Steinbusch HW, Bolkunov A, Nunes J, Santos AI, Grandfils C, Bachurin S, Strekalova T (2011) Dimebon enhances hippocampus-dependent learning in both appetitive and inhibitory memory tasks in mice. Prog Neuropsychopharmacol Biol Psychiatry 35, 510-522
26. Webster SJ, Wilson CA, Lee CH, Mohler EG, Terry AV, Jr., Buccafusco JJ (2011) The acute effects of dimebolin, a potential Alzheimer's disease treatment, on working memory in rhesus monkeys. Br J Pharmacol 164, 970-978
27. Wu J, Li Q, Bezprozvanny I (2008) Evaluation of Dimebon in cellular model of Huntington's disease. Mol Neurodegener 3, 15